Cancer Cell Biology

癌细胞生物学

• 批准号: 7944540
• 负责人: M. LUISA IRUELA-ARISPE
• 金额: $ 5.59万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-02 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944540
• 关键词: Achievement; Animal Model; Area; Basic Science; Biological; Biological Models; Biological Sciences; Biology; Biomedical Research; Biomedical Technology; California; Cancer Biology; Cancer Center Support Grant; Cancer Detection; Cells; Cellular biology; Chemistry; Chin; Clinical; Collaborations; Communities; Complement; Comprehensive Cancer Center; Consultations; Core Facility; Critiques; Derivation procedure; Detection; Development; Developmental Biology; Developmental Cell Biology; Developmental Process; Drosophila genus; Drug Delivery Systems; Educational workshop; Emerging Technologies; Engineering; Faculty; Failure; Focus Groups; Fostering; Funding; Genetic; Genetic Screening; Gifts; Goals; Grant; Hemangioma; Hospitals; Housing; Information Dissemination; Institutes; Interest Group; Investments; Joint Ventures; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Knowledge; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of prostate; Mammary Neoplasms; Modeling; Molecular; Monitor; Mutation; Names; Nanotechnology; National Cancer Institute; Paper; Participant; Pathologist; Pathway interactions; Peer Review; Positioning Attribute; Preventive; Publications; Publishing; Reagent; Recruitment Activity; Refractory; Reporting; Research; Research Infrastructure; Research Personnel; Resource Sharing; Rome; Science; Scientist; Screening procedure; Seeds; Series; Signal Transduction; Stem Cell Research; Stem cells; Strategic Planning; Subgroup; The Sun; Therapeutic; Therapeutic Studies; Translations; Tumorigenicity; Universities; Ursidae Family; Work; Zebrafish; anticancer research; base; cancer cell; cancer stem cell; cancer therapy; cost; frontier; human disease; improved; innovation; insight; interest; member; metaplastic cell transformation; mouse model; nanobiology; nanosystems; neoplastic cell; outcome forecast; paracrine; pre-clinical; prognostic; programs; response; stem; stem cell biology; symposium; tumor; tumor growth; tumor progression

The CCB Program Area has 24 core members, distributed among these three focus areas. During the current funding year, peer-reviewed funding totaled $12 million in total costs, including $1.45 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CCB Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CCB Program Area total $1,042,520. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support. Cancer Cell Biology Program Area members published 201 peer-reviewed papers during the recent five-year renewal period. The JCCC CCB program area is highly interactive, with 9% of its 201 publications reflecting intraprogrammatic efforts and 59% reporting inter-programmatic collaborations. 129 publications (64%) appeared in high-impact journals. The Cancer Cell Biology (CCB) Program Area was previously named the "Molecular, Cellular and Developmental Biology (MCDB) Program Area." In response to the 2002 CCSG review, and in extensive consultation with our External Advisory Board, the JCCC has reorganized this program. The goals of the reorganization were to: (1) identify critical cancer-relevant focus areas of basic science and biomedical technologies; (2) identify appropriate leaders and members for these focus areas; (3) promote intraprogrammatic interactions and collaborations within and across these groups in cancer-related areas; and (4) foster inter-programmatic interactions leading to translational and clinical collaboration. Concomitantly with the interest in reorganizing this program area, UCLA had made the strategic decision to invest heavily in infrastructure, faculty recruitment and funding in nanotechnology and stem cell biology; the California NanoSystems Institute and the Broad Stem Cell Center (BSCC) have both been created during the current JCCC CCSG funding cycle, and new buildings constructed to house these programs. The JCCC capitalized and incorporated the investment made by UCLA into our Program Area strategic plan and identified three main interest groups for the Cancer Cell Biology Program Area: (1) nanobiology applications to cancer detection, monitoring, and therapy; (2) cancer stem cell identification and eradication; and (3) model organism studies of cancer detection, progression, and therapy. Senior Associate Dean Dr. Leonard Rome, the former MCDB Program Area director, has become the JCCC Director for Strategic Planning and Partnerships. With the enthusiastic support of our EAB, Dr. Luisa Iruela-Arispe, an internationally known developmental biologist and cancer researcher has become the Director of the CCB Program Area. Dr. Michael Teitell, a pathologist and cancer biologist with strong interests in nanotechnology, brings strength in this area and a clinical perspective to the Co-Director position.

CCB计划区有24个核心成员，分布在这三个重点领域。在电流期间 资助年，同行评审的资金总成本为1200万美元，其中包括来自国家的145万美元 癌症研究所。与其他计划领域一样，JCCC培养了许多互动活动和许多 共享资源，支持CCB计划领域的研究人员。在当前的赠款周期中，资金 从JCCC以CCSG发展基金，机构支持和慈善礼物的形式到 CCB计划区域总计$ 1,042,520。这些资金支持跨学科的赠款，种子补助， 招聘/保留，计划领域的领导力支持，使用新兴共享资源的资金 和受训者。计划区域成员中有十二名是JCCC支持的接受者。癌细胞 在最近的五年续签期间，生物学计划区域成员发布了201次同行评审论文 时期。 JCCC CCB计划领域高度互动，其201个出版物中有9％反映了磁内图 努力和59％的报告跨编程间合作。出现了129个出版物（64％） 在高影响期刊中。 癌细胞生物学（CCB）程序区域先前被命名为“分子，细胞和 发展生物学（MCDB）计划领域。 与我们的外部顾问委员会协商，JCCC重组了该计划。目标的目标 重组是：（1）确定基础科学和生物医学的关键关键重点领域 技术； （2）确定这些重点领域的适当领导者和成员； （3）促进术中 这些群体与癌症相关地区的这些群体内部和之间的互动和合作； （4） 促进策略间相互作用，导致转化和临床协作。同时与 对重组该计划领域的兴趣，加州大学洛杉矶分校做出了战略决定，以进行大量投资 纳米技术和干细胞生物学的基础设施，教师招聘和资金；加利福尼亚 纳米系统研究所和宽干细胞中心（BSCC）都是在当前创建的 JCCC CCSG融资周期和用于容纳这些计划的新建筑物。 JCCC大写 并将UCLA投资纳入我们的计划领域战略计划，并确定了三个主要 癌细胞生物学计划领域的利益组：（1）纳米生物学应用于癌症检测， 监测和治疗； （2）癌症干细胞鉴定和消除； （3）模型的生物研究 癌症检测，进展和治疗。高级副院长伦纳德·罗马博士，前MCDB 计划区总监已成为JCCC战略规划和合作伙伴关系主管。与 我们的EAB的热情支持Luisa Iruela-Arispe博士，国际知名的发展生物学家 癌症研究员已成为CCB计划领域的主任。病理学家迈克尔·泰特尔博士 以及对纳米技术有浓厚兴趣的癌症生物学家，在该领域带来了力量和临床 与联合导演位置的观点。